Myopia control with MiSight® 1-day contact lenses: a case series

Authors

  • Ana Gonçalves Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa. Lisboa, Portugal.
  • Maria Narciso Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa. Lisboa, Portugal.
  • Maria Eduarda Martins Zona Óptica. Lisboa, Portugal.
  • Susana Plácido Departamento das Ciências da Terapia e Reabilitação, Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa. Lisboa, Portugal.
  • Luís Mendanha Departamento das Ciências da Terapia e Reabilitação, Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa. Lisboa, Portugal.
  • Carla Lança Departamento das Ciências da Terapia e Reabilitação, Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa. Lisboa, Portugal | Comprehensive Health Research Center (CHRC), Escola Nacional de Saúde Pública, Universidade Nova de Lisboa. Lisboa, Portugal.

DOI:

https://doi.org/10.25758/set.608

Keywords:

Myopia, Children, Contact lenses, MiSight 1 day, Myopia management

Abstract

Introduction Myopia is a refractive error where parallel rays coming from infinity focus before the retinal plane. Globally the prevalence of myopia has increased, and its progression can be controlled by various methods, including peripheral defocusing lenses, such as the MiSight® 1-day contact lenses. Objectives Evaluate the progression of myopia in children who wore MiSight® 1-day contact lenses. Methods This was an observational, descriptive, retrospective, and case series study. Data was collected from clinical registries in an Optician’s office, where the contact lenses were fitted. Children with myopia who started treatment with MiSight® 1 day contact lenses to control myopia progression were included. Treatment efficacy was assessed by measuring refractive error (spherical equivalent) before, during, and after initiation of treatment. Results Five children were included, two males and three females, aged between seven and fifteen years. The duration of treatment ranged from 19 to 61 months. Myopia progression during treatment ranged from 0.00 to -1.75 D. Discussion All children in the study showed a decrease in myopia progression compared to myopia progression before treatment (0.00 and -2.25 D), as well as to what would be expected without treatment (-1.10 and -2.75 D). Conclusions The use of MiSight® 1-day provided greater control over the progression of myopia when compared to the progression that would be expected without its use.

Downloads

Download data is not yet available.

References

Flitcroft DI, He M, Jonas JB, Jong M, Naidoo K, Ohno-Matsui K, et al. IMI – Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019;60(3):M20-30.

Baird PN, Saw SM, Lanca C, Guggenheim JA, Smith III EL, Zhou X, et al. Myopia. Nat Rev Dis Primers. 2020;6(1):99.

Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-42.

McCullough SJ, O’Donoghue L, Saunders KJ. Six year refractive change among white children and young adults: evidence for significant increase in myopia among white UK children. PLoS One. 2016;11(1):e0146332.

Pärssinen O, Kauppinen M. Associations of near work time, watching TV, outdoors time, and parents’ myopia with myopia among school children based on 38‐year‐old historical data. Acta Ophthalmol. 2021;100(2):e430-8.

Foreman J, Salim AT, Praveen A, Fonseka D, Ting DS, He MG, et al. Association between digital smart device use and myopia: a systematic review and meta-analysis. Lancet Digit Health. 2021;3(12):e806-18.

Mountjoy E, Davies NM, Plotnikov D, Smith GD, Rodríguez S, Williams CE, et al. Education and myopia: assessing the direction of causality by mendelian randomisation. BMJ. 2018;361:k2022.

Donovan L, Sankaridurg P, Ho A, Naduvilath T, Smith 3rd EL, Holden BA. Myopia progression rates in urban children wearing single-vision spectacles. Optom Vis Sci. 2012;89(1):27-32.

Hu Y, Ding X, Long W, He M, Yang X. Longitudinal changes in spherical equivalent refractive error among children with preschool myopia. Invest Ophthalmol Vis Sci. 2019;60(1):154-60.

Ma Y, Zou H, Lin S, Xu X, Zhao R, Lu L, et al. Cohort study with 4-year follow-up of myopia and refractive parameters in primary schoolchildren in Baoshan District, Shanghai. Clin Exp Ophthalmol. 2018;46(8):861-72.

French AN, Morgan IG, Burlutsky G, Mitchell P, Rose KA. Prevalence and 5- to 6-year incidence and progression of myopia and hyperopia in Australian schoolchildren. Ophthalmology. 2013;120(7):1482-91.

Pärssinen O, Lyyra AL. Myopia and myopic progression among schoolchildren: a three-year follow-up study. Invest Ophthalmol Vis Sci. 1993;34(9):2794-802.

Loh KL, Lu Q, Tan D, Chia A. Risk factors for progressive myopia in the atropine therapy for myopia study. Am J Ophthalmol. 2015;159(5):945-9.

Fan DS, Lam DS, Lam RF, Lau JT, Chong KS, Cheung EY, et al. Prevalence, incidence, and progression of myopia of school children in Hong Kong. Invest Ophthalmology Vis Sci. 2004;45(4):1071-5.

Lam CS, Edwards M, Millodot M, Goh WS. A 2-year longitudinal study of myopia progression and optical component changes among Hong Kong schoolchildren. Optom Vis Sci. 1999;76(6):370-80.

Hsu CC, Huang N, Lin PY, Fang SY, Tsai DC, Chen SY, et al. Risk factors for myopia progression in second-grade primary school children in Taipei: a population-based cohort study. Br J Ophthalmol. 2017;101(12):1611-7.

Bullimore MA, Ritchey ER, Shah S, Leveziel N, Bourne RR, Flitcroft DI. The risks and benefits of myopia control. Ophthalmology. 2021;128(11):1561-79.

Modjtahedi BS, Ferris 3rd FL, Hunter DG, Fong DS. Public health burden and potential interventions for myopia. Ophthalmology. 2018;125(5):628-30.

Haarman AE, Enthoven CA, Tideman JW, Tedja MS, Verhoeven VJ, Klaver CC. The complications of myopia: a review and meta-analysis. Invest Ophthalmology Vis Sci. 2020;61(4):49.

Ohno-Matsui K, Lai TY, Lai CC, Cheung CM. Updates of pathologic myopia. Prog Retin Eye Res. 2016;52:156-87.

Jonas JB, Ang M, Cho P, Guggenheim JA, He MG, Jong M, et al. IMI prevention of myopia and its progression. Invest Ophthalmol Vis Sci. 2021;62(5):6.

Wildsoet CF, Chia A, Cho P, Guggenheim JA, Polling JR, Read S, et al. IMI – Interventions Myopia Institute: interventions for controlling myopia onset and progression report. Invest Ophthalmology Vis Sci. 2019;60(3):M106-131.

Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019;96(8):556-67.

Chamberlain P, Bradley A, Arumugam B, Hammond D, McNally J, Logan NS, et al. Long-term effect of dual-focus contact lenses on myopia progression in children: a 6-year multicenter clinical trial. Optom Vis Sci. 2022;99(3):204-12.

Tricard D, Marillet S, Ingrand P, Bullimore MA, Bourne RR, Leveziel N. Progression of myopia in children and teenagers: a nationwide longitudinal study. Br J Ophthalmol. 2022;106(8):1104-9.

Chamberlain P, Arumugam B, et al. Myopia progression on cessation of dual-focus contact lens wear: MiSight 1 day 7-year findings. Optom Vis Sci. 2021;98:e210049.

Cabanes‐Martí E, García‐Ayuso D. Myopia control with dual‐focus soft contact lenses during the first year of measures to contain the COVID-19 pandemic. Ophthalmic Physiol Opt. 2022;42(6):1227-31.

Published

2023-12-30

Issue

Section

Artigos

How to Cite

Myopia control with MiSight® 1-day contact lenses: a case series. (2023). Saúde & Tecnologia, 29, e608. https://doi.org/10.25758/set.608